Abstract:Hepatitis B and its sequelae are a major public health problem. Vaccines have been available for almost 20 years; however the disease still remains a global problem. Many factors contribute to the failure to control hepatitis B, including the limited nature of the vaccination programs implemented initially. Only relatively recently has mass childhood vaccination begun to be implemented and vaccination of high-risk groups, other than healthcare workers, is still not general policy. Additional factors contributi… Show more
“…Its seroconversion rate reached 95.05%, a rate significantly higher than those of the other three groups. This seroconversion rate was also similar to that of the 20 μg hepatitis B vaccine reported by Young et al (2001). This similarity might be caused by the high purity of the Hansenula hepatitis B vaccine, which uses a chemosynthesis complete medium only, and not a selective medium, peptone or yeast powder.…”
Section: Discussionsupporting
confidence: 84%
“…This similarity might be caused by the high purity of the Hansenula hepatitis B vaccine, which uses a chemosynthesis complete medium only, and not a selective medium, peptone or yeast powder. The seroconversion rates of the 10 μg hepatitis B vaccine produced by the North China Pharmaceutical Company and GlaxoSmithKline were slightly higher than that of the 10 μg hepatitis B vaccine previously reported by Young et al (2001). Regarding the anti-HBs GMT, the immune effects for all the vaccines were good, except those of the Shenzhen Kangtai vaccine.…”
“…Its seroconversion rate reached 95.05%, a rate significantly higher than those of the other three groups. This seroconversion rate was also similar to that of the 20 μg hepatitis B vaccine reported by Young et al (2001). This similarity might be caused by the high purity of the Hansenula hepatitis B vaccine, which uses a chemosynthesis complete medium only, and not a selective medium, peptone or yeast powder.…”
Section: Discussionsupporting
confidence: 84%
“…This similarity might be caused by the high purity of the Hansenula hepatitis B vaccine, which uses a chemosynthesis complete medium only, and not a selective medium, peptone or yeast powder. The seroconversion rates of the 10 μg hepatitis B vaccine produced by the North China Pharmaceutical Company and GlaxoSmithKline were slightly higher than that of the 10 μg hepatitis B vaccine previously reported by Young et al (2001). Regarding the anti-HBs GMT, the immune effects for all the vaccines were good, except those of the Shenzhen Kangtai vaccine.…”
“…Although limited data are available, small studies have reported improved seroconversion rates in obese patients with increasing needle length, dose and formulation of vaccine, and weight reduction surgery. [21][22][23][24] Other factors that have been found to correlate poorly with immune response such as smoking and age were not associated with seroconversion in our cohort. Compliance rates for hepatitis B vaccination completion varies depending on the population.…”
An accelerated hepatitis B vaccination schedule at 0, 1, and 4 months in high-risk pregnant women is effective, practical, and well tolerated. This accelerated vaccine strategy can be completed during the course of pregnancy and provides another means of decreasing hepatitis B virus disease and transmission.
“…Further, Simo Minnana et al reported lower antibody response in adolescents with high BMI when administered a three-dose regimen of recombinant hepatitis B vaccine (20). A randomized controlled trial compares triple-antigen vaccine vs standard single antigen vaccine administered in three doses over six months resulted in 71% and 95% protection rates in obese subjects when compared with lean subjects (91% & 99% respectively) (21). Therefore, the purpose of this study was to examine the correlation between body mass index, serum alanine aminotransferase activity and immunologic response in obese hepatitis B virus patients.…”
Background & Objective:Chronic B viral hepatitis is a major health problem worldwide. Several studies have reported that obesity is important risk factors altered immune system response in individuals with no underlying causes of liver disease. This study was to examine the correlation between body mass index, serum alanine aminotransferase activity and immunologic response in obese hepatitis B Saudi patients. Subjects and Methods: One hundred fifty Saudi male patients with hepatitis B viral infection (HBV); their age ranged from 30 to 45 (38.64 ± 7.12) years. Patients were divided in to two equal groups according to their body mass index: Group (A): Included patients with HBV, their body mass index (BMI) was greater than 30 kg/m 2 (the obese group). Group (B): Included patients with HBV, their BMI between 20 and 24 kg/m 2 (the normal-weight group). Results: An elevation of serum alanine aminotransferase (ALT) activity was found to be associated with increased BMI, also we observed an elevation with regard to the normal weight group in the parameters of white blood cells, neutrophils, monocytes, CD3, CD4 and CD8 for group A. CD3, CD4 and CD8 correlated with BMI only as a total amount, as well as with all measured parameters of blood count. Conclusion: Obesity adversely affects the immunological response and rate of disease progression in HBeAg-negative chronic hepatitis B viral infection. Body weight control is important in the management of patients with chronic hepatitis B viral infection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.